Pathology & Laboratory Medicine

Publications

Filter By Faculty

Filter by Principal Investigator

2022

Farnsworth MC, Zhao Z, Apple EF, Collinson P, DeMarco ML, Gronowski A, et al. Critical Roles of Clinical Laboratorians in Translational Research and Applied Sciences-Experts' Insights and Experiences. Clin Chem. 2022;68(7):877-883.

Wulff RT, Qiu Y, Wu C, Calfee DP, Singh HK, Hatch I, et al. Laboratory Interventions to Eliminate Unnecessary Rapid COVID-19 Testing During a Reagent Shortage. Am J Clin Pathol. 2022;158(3):401-408.

Chen B-, Tyler JK, Sleckman BP. A Flow Cytometry-Based Method for Analyzing DNA End Resection in G0- and G1-Phase Mammalian Cells. Bio Protoc. 2022;12(10):e4413.

Webster AL, Sanders MA, Patel K, Dietrich R, Noonan RJ, Lach FP, et al. Genomic signature of Fanconi anaemia DNA repair pathway deficiency in cancer. Nature. 2022;612(7940):495-502.

Rosenthal J, Carelli R, Omar M, Brundage D, Halbert E, Nyman J, et al. Building Tools for Machine Learning and Artificial Intelligence in Cancer Research: Best Practices and a Case Study with the PathML Toolkit for Computational Pathology. Mol Cancer Res. 2022;20(2):202-206.

Haigh DB, Woodcock CL, Lothion-Roy J, Harris AE, Metzler VM, Persson JL, et al. The METTL3 RNA Methyltransferase Regulates Transcriptional Networks in Prostate Cancer. Cancers (Basel). 2022;14(20).

Weinberg OK, Siddon A, Madanat YF, Gagan J, Arber DA, Dal Cin P, et al. TP53 mutation defines a unique subgroup within complex karyotype de novo and therapy-related MDS/AML. Blood Adv. 2022;6(9):2847-2853.

Jang J-, Hwang I, Pan H, Yao J, Alinari L, Imada E, et al. A FOXO1-dependent transcription network is a targetable vulnerability of mantle cell lymphomas. J Clin Invest. 2022;132(24).

Cyrta J, Prandi D, Arora A, Hovelson DH, Sboner A, Rodriguez A, et al. Comparative genomics of primary prostate cancer and paired metastases: insights from 12 molecular case studies. J Pathol. 2022;257(3):274-284.

Boyraz B, Tajiri R, Alwaqfi RR, Paula AD, Ye Q, G Nielsen P, et al. Vulvar angiomyofibroblastoma is molecularly defined by recurrent MTG1-CYP2E1 fusions. Histopathology. 2022;81(6):841-846.